{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Progression of disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Will be measured by CT scan /MRI of the head and neck with corroborative results of direct biopsy of any residual tumor at primary site.","groups":[{"description":"Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \\& Radiation Therapy\n\ncetuximab\n\ncisplatin\n\ndocetaxel\n\nfluorouracil\n\ncomputed tomography\n\npositron emission tomography\n\nquality-of-life assessment\n\n3-dimensional conformal radiation therapy\n\nintensity-modulated radiation therapy","id":"OG000","title":"TPFChemotherapy + Concomitant Cetuximab & RT"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}